Teva Pharmaceutical news from FiercePharma
News
Amgen profits drop, Teva's grow
It's a good news-bad news day on the earnings side, with Amgen reporting a drop in profits, but a boost in its 2008 forecast, and Ranbaxy earnings on the flat side, while Teva's are on the rise. Here Read more...
Teva seeks venture partner in Japan
Fresh off its $7.5 billion deal to buy Barr Pharmaceuticals, Teva is eyeing joint ventures in Japan. CEO Shlomo Yanai told the Financial Times that establishing a beachhead in that country is a top Read more...
Teva gets approval to buy Bentley
Teva Pharmaceutical Industries received nearly a 69 percent shareholder approval to complete its $360 million dollar purchase of Bentley Pharmaceuticals, a move the company hopes will help it to Read more...
It's Teva plus Barr in a $7.46B buyout
It's official: Teva and Barr are getting hitched. It's a $7.46 billion cash-and-stock deal that will combine the world's largest and fourth-largest generics makers into one big copycat drug Read more...
Rumor mill: Teva mulling $7.5B deal for Barr
The world's biggest generics firm may be about to get bigger -- lots bigger. Teva is reportedly in talks to buy Barr Pharmaceuticals for upwards of $5 billion; some reports quote a price as high as Read more...
Teva faces double Copaxone woes
Israeli generics giant Teva Pharmaceutical Industries is suffering a couple of Copaxone-related headaches. First, Israel's health ministry appointed a special committee to probe a trial of the MS Read more...
AstraZeneca wins Seroquel patent fight
AstraZeneca is celebrating today -- or at least relaxing a bit. It has avoided a full-blown trial today to protect its top-selling antipsychotic medication, Seroquel. The trial would have taken Read more...
J&J fights Teva with generic Risperdal
It's a watershed moment: Risperdal has gone generic. The Johnson & Johnson antipsychotic med now has copycat competition from Teva Pharmaceutical Industries, which got the final FDA go-ahead Read more...
Mylan to sell copycat of Teva MS drug
Here's a turnabout-is-fair-play story. Generics maker Teva Pharmaceuticals, known for its aggressive challenges to brand-name drugs, is getting challenged itself. The company has one very big branded Read more...
Vasella: 'Teva is better than we are'
Novartis CEO Daniel Vasella has a knack for the quotable quote. Here's the latest: "Teva is better than we are, and that's hard to Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets